Losing CD45 and various B-cell markers in a case of MYC-driven pediatric high-grade B-cell lymphoma, not otherwise specified that transformed from Burkitt’s lymphoma during rituximab-containing treatments: a case report
Archiv für pathologische Anatomie und Physiologie und für klinische Medicin - Tập 483 - Trang 111-116 - 2022
Tóm tắt
In this study, we reported a seldom case of pediatric high-grade B-cell lymphoma, not otherwise specified (HGBL, NOS) with loss of B-cell markers (CD19, CD20, CD22, CD79a, CD38, Pax5, OCT2, and BOB1) and CD45, which bring great challenges to exclude a non-lymphomatous neoplasm. However, no evidence was found to support the diagnosis of sarcoma and carcinoma. Thus, due to the patient’s prior history of Burkitt’s lymphoma treated by rituximab-containing therapies, we carefully searched for any indication of B-cell differentiation. Eventually, NGS results revealed the monoclonal rearrangement of IGH (IGHD2-8-IGHJ6 and IGHV4-30–2-IGHJ4) in both pre-treatment and present tumors, confirming the same B-cell lineage. Moreover, both tumors exhibited the same IGHA1-MYC translocation and somatic mutations of c-MYC, TP53, ID3, and CCND3. Therefore, in addition to strong expression of BCL2 in the present tumor, we finally arrived at a diagnosis of pediatric HGBL, NOS with loss of B-cell lineage markers and CD45.
Tài liệu tham khảo
Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ (2008) Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res: Off J Am Assoc Cancer Res 14:1561–1570. https://doi.org/10.1158/1078-0432.CCR-07-1254
Nakamaki T, Fukuchi K, Nakashima H, Ariizumi H, Maeda T, Saito B, Yanagisawa K, Tomoyasu S, Homma M, Shiozawa E, Yamochi-Onizuka T, Ota H (2012) CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma. Eur J Haematol 89:350–355. https://doi.org/10.1111/j.1600-0609.2012.01838.x
Rawal YB, Nuovo GJ, Frambach GE, Porcu P, Baiocchi RA, Magro CM (2005) The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. J Cutan Pathol 32:616–621. https://doi.org/10.1111/j.0303-6987.2005.00305.x
Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Mishima Y, Kuniyoshi R, Taniyama A, Yokoyama M, Sakajiri S, Takeuchi K, Watanabe C, Takahashi S, Ito Y, Hatake K (2009) Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin’s lymphoma. Clin Cancer Res: Off J Am Assoc Cancer Res 15:2523–2530. https://doi.org/10.1158/1078-0432.CCR-08-1403
Donner LR, Mott FE, Tafur I (2001) Cytokeratin-positive, CD45-negative primary centroblastic lymphoma of the adrenal gland: a potential for a diagnostic pitfall. Arch Pathol Lab Med 125:1104–1106. https://doi.org/10.5858/2001-125-1104-CPCNPC
Jha B, Mohapatra I, Gajendra S, Sachdev R (2015) CD45-negative primary diffuse large B-cell lymphoma of the cerebellum. Neurol India 63:276–279. https://doi.org/10.4103/0028-3886.156311
Palmeira C, Sousa ME, Godinho I, Pires AM, Mendes C, Martins G (2012) Flow cytometry CD45-negative B-NHL: a case report of a diffuse large B-cell lymphoma without extranodal involvement Cytometry. Part B, Clinical cytometry 82:369–371. https://doi.org/10.1002/cyto.b.21038
Seitz V, Butzhammer P, Hirsch B, Hecht J, Gutgemann I, Ehlers A, Lenze D, Oker E, Sommerfeld A, von der Wall E, Konig C, Zinser C, Spang R, Hummel M (2011) Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PloS one 6:e26837. https://doi.org/10.1371/journal.pone.0026837
Fan J, Zeller K, Chen YC, Watkins T, Barnes KC, Becker KG, Dang CV, Cheadle C (2010) Time-dependent c-Myc transactomes mapped by array-based nuclear run-on reveal transcriptional modules in human B cells. PloS one 5:e9691. https://doi.org/10.1371/journal.pone.0009691
Wu D, Wood BL, Dorer R, Fromm JR (2010) “Double-hit” mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression. Am J Clin Pathol 134:258–265. https://doi.org/10.1309/AJCP7YLDTJPLCE5F
Newman AM, Zaka M, Zhou P, Blain AE, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Enshaei A, De Zordi J, Harding F, Taj M, Wood KM, Televantou D, Turner SD, Burke GAA, Harrison CJ, Bomken S, Bacon CM, Rand V (2022) Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. Leukemia 36:781–789. https://doi.org/10.1038/s41375-021-01444-6